/
OMER
$16.92+$3.64 (+26.55%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$992.3M
72M shares
52-week range
$3.94 – $18.14
91% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change+$2.67
Omeros Corporation
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
www.omeros.com- Employees
- 175
- IPO / List date
- Oct 8, 2009
- HQ
- SEATTLE, WA
Held by traders on TradeandTell
No one on the platform currently holds OMER.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 344,500 | $1.4M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded OMER yet.
